Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RADg62fTypZ-lEO6r37XWlco1fzPGkv6ikX94J399I3Tg#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _4 label "Selventa" provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- large_corpus.bel version "20131211" provenance.
- large_corpus.bel authoredBy _4 provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- assertion wasDerivedFrom _3 provenance.
- assertion hadPrimarySource 16034410 provenance.
- _3 wasQuotedFrom 16034410 provenance.
- _3 value "There was no difference in the magnitude of serum RBP4 elevation between the obese and obese-diabetic groups, suggesting that obesity and insulin resistance, but not hyperglycaemia, are associated with elevated serum RBP4 in humans. Rosiglitazone reverses RBP4 elevation The anti-diabetic agent rosiglitazone is a peroxisome proliferator activated receptor-gamma (PPARg) agonist that improves insulin sensitivity17. Treatment of adipose-Glut4-/- mice with rosiglitazone for three weeks completely reversed their insulin resistance and glucose intolerance18." provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.